Depression - Major Depressive Disorder

Neurology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Verona Pharma
Verona PharmaUK - London
1 program
1
Hyperbolic taperingPhase 41 trial
Active Trials
NCT07393919Not Yet Recruiting150Est. Sep 2027
I
IQVIANC - Durham
1 program
Real-world Clinical Response to Trazodone in Italy, Poland, and RomaniaN/A1 trial
Active Trials
NCT07377682Recruiting120Est. Jul 2026

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Verona PharmaHyperbolic tapering
IQVIAReal-world Clinical Response to Trazodone in Italy, Poland, and Romania

Clinical Trials (2)

Total enrollment: 270 patients across 2 trials

NCT07393919Verona PharmaHyperbolic tapering

Discontination of Antidepressants in Remitted Depression

Start: Feb 2026Est. completion: Sep 2027150 patients
Phase 4Not Yet Recruiting
NCT07377682IQVIAReal-world Clinical Response to Trazodone in Italy, Poland, and Romania

Real-world Clinical Response to Trazodone in Italy, Poland, and Romania

Start: Dec 2025Est. completion: Jul 2026120 patients
N/ARecruiting

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 270 patients
2 companies competing in this space